PDI Moves into MDx Space with Acquisition of Two Asuragen microRNA Tests | GenomeWeb

NEW YORK (GenomeWeb) – PDI said after the close of the market Wednesday that its Interpace Diagnostics subsidiary will enter the molecular diagnostics market through the acquisition of two tests from Asuragen.

PDI said that it will pay Asuragen $8 million upfront in cash, future commercial milestone-based payments, and royalties for the miRInform Thyroid and Pancreas cancer tests, IP related to the tests and other tests in development for thyroid cancer, as well as a tissue sample biobank containing more than 5,000 samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.